Do Statins Reduce the Health and Health Care Costs of Obesity?

PharmacoEconomics

Volumn 33, Issue 7, 2015, Pages 723-734

  Gaudette, Étienne ^a   Goldman, Dana P ^a   Messali, Andrew ^a   Sood, Neeraj ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTICLE; BODY MASS; CEREBROVASCULAR ACCIDENT; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG COST; FUNCTIONAL STATUS; HEALTH CARE COST; HEALTH STATUS; HEART DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; LIFE EXPECTANCY; MEDICAID; MEDICARE; OBESITY; OBESITY ASSOCIATED ILLNESS; PHYSICAL DISEASE BY ETIOLOGY AND PATHOGENESIS; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK REDUCTION; AGED; COMPUTER SIMULATION; COST BENEFIT ANALYSIS; ECONOMIC MODEL; ECONOMICS; MARKOV CHAIN; STATISTICS AND NUMERICAL DATA; TRENDS;

AGED; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; HEALTH CARE COSTS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIFE EXPECTANCY; MARKOV CHAINS; MODELS, ECONOMIC; OBESITY; QUALITY-ADJUSTED LIFE YEARS;

EID: 84933529691     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-014-0234-y     Document Type: Article

References (25)

1. Fryar CD, Carrol MD, Ogden CL. Prevalence of overweight, obesity, and extreme obesity among adults: United States, Trends 1960–1962 Through 2009–2010. National Center for Health Statistics: Hyattsville; 2012.
2. James WPT, Jackson-Leach R, Mhurchu CN, Kalamara E, Shayeghi M, Rigby NJ, Nishida C, Rodgres A. Chapter 8: overweight and obesity (high body mass index). In: Ezzati M, Lopez AD, Rodgers A, Murray CJL. Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors. Volume 1. Geneva: World Health Organization; 2004, p. 497–596.
3. Colditz GA. Economic costs of obesity. Am J Clin Nutr. 1992;55(2 Suppl):503S–7S.
4. Finkelstein EA, Fiebelkorn IC, Wang G. National medical spending attributable to overweight and obesity: how much, and who’s paying? Health Aff. 2003;Suppl Web Exclusives:W3-219–26.
5. Finkelstein EA, Trogdon JG, Cohen JW, Dietz W. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff. 2009;28(5):w822–31.
6. Cawley J, Meyerhoefer C. The medical care costs of obesity: an instrumental variables approach. J Health Econ. 2012;31(1):219–30.
7. Chen YH, Feng B, Chen ZW. Statins for primary prevention of cardiovascular and cerebrovascular events in diabetic patients without established cardiovascular diseases: a meta-analysis. Exp Clin Endocrinol Diabetes. 2012;120(2):116–20.
8. Cholesterol Treatment Trialists Collaborators, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–90.
9. de Vries FM, Denig P, Pouwels KB, Postma MJ, Hak E. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis. Drugs. 2012;72(18):2365–73.
10. Gutierrez J, Ramirez G, Rundek T, Sacco RL. Statin therapy in the prevention of recurrent cardiovascular events: a sex-based meta-analysis. Arch Intern Med. 2012;172(12):909–19.
11. Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, et al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. QJM. 2011;104(2):109–24.
12. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816.
13. Grabowski DC, Lakdawalla DN, Goldman DP, Eber M, Liu LZ, Abdelgawad T, et al. The large social value resulting from use of statins warrants steps to improve adherence and broaden treatment. Health Aff. 2012;31(10):2276–85.
14. Michaud PC, Goldman DP, Lakdawalla DN, Zheng Y, Gailey AH. The value of medical and pharmaceutical interventions for reducing obesity. J Health Econ. 2012;31(4):630–43.
15. Livingston EH. The incidence of bariatric surgery has plateaued in the US. Am J Surg. 2010;200(3):378–85.
16. Goldman DM, et al. Health status and medical treatment of the future elderly: final report. Santa Monica: RAND Corp; 2004.
17. Bhattacharya J, Shang B, Su CK, Goldman DP. Technological advances in cancer and future spending by the elderly. Health Aff. 2005;24 Suppl 2:W5R53–66.
18. Lakdawalla DN, Goldman DP, Shang B. The health and cost consequences of obesity among the future elderly. Health Aff. 2005;24 Suppl 2:W5R30–41.
19. Goldman DP, Zheng Y, Girosi F, Michaud PC, Olshansky SJ, Cutler D, et al. The benefits of risk factor prevention in Americans aged 51 years and older. Am J Public Health. 2009;99(11):2096–101.
20. Bhattacharya J, Sood N. Who pays for obesity? J Econ Perspect. 2011;25(1):139–58.
21. Merrill RM, Richardson JS. Validity of self-reported height, weight, and body mass index: findings from the National Health and Nutrition Examination Survey, 2001–2006. Prev Chronic Dis. 2009;6(4):A121.
22. Macroeconomics and Health. Investing in health for economic development. Geneva: World Health Organization; 2001. p. 2001.
23. Sugiyama T, Tsugawa Y, Tseng CH, Kobayashi Y, Shapiro MF. Different time trends of caloric and fat intake between statin users and nonusers among us adults: gluttony in the time of statins? JAMA Intern Med. 2014;174:1038–45.
24. Kaestner R, Darden M, Lakdawalla D. Are investments in disease prevention complements? The case of statins and health behaviors. J Health Econ. 2014;36:151–63.
25. Wei L, Ebrahim S, Bartlett C, Davey PD, Sullivan FM, MacDonald TM. Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. Bmj. 2005;330(7495):821.